



#  
12/B

Attorney Docket: 1064/48505  
PATENT

25-1-20

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MARC G. ACHEN ET AL.  
Serial No.: 09/761,636 Group Art Unit: 1644  
Filed: JANUARY 18, 2001 Examiner: Phuong N. HUYNH  
Title: VEGF-D/VEGF-C/VEGF PEPTIDOMIMETIC INHIBITORS

REPLY

RECEIVED

Commissioner for Patents  
Washington, D.C. 20231

JAN 06 2003  
TECH CENTER 1600/2900

Sir:

The following amendment and remarks are responsive to the Office Action mailed July 2, 2002. This response is timely by virtue of the Petition for a three-month extension of time and the requisite fees concurrently submitted herewith.

IN THE SPECIFICATION:

Please amend the specification as follows (a marked-up version of the specification as amended is attached hereto):

Please replace the paragraph beginning on page 29, line 21 with the following:

81  
Initial homology modelling for VEGF-D was carried out using the Swiss-Model automated protein homology server running at the Glaxo Institute for Molecular Biology in Geneva, Switzerland, accessed via the Internet (See Peitsch, 1995). In the C-terminal 23 amino acid residues of the sequences used for modeling there is low homology between VEGF-D and VEGF. Therefore a theoretical hybrid molecule was generated whose N-terminus consists of amino acids Val<sup>101</sup> - Thr<sup>173</sup> of VEGF-D (SEQ ID NO:3) and whose C-terminus consists of Gln<sup>113</sup> - Asp<sup>135</sup> of VEGF<sub>165</sub> (SEQ ID NO:4). Thus the C-terminal 23 residues of